Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic <i>BRAF</i> Wild-Type Anaplastic Thyroid Carcinoma
Sarah Hamidi(The University of Texas MD Anderson Cancer Center), Ramona Dadu(The University of Texas MD Anderson Cancer Center), Mark Zafereo(The University of Texas MD Anderson Cancer Center), Anna F. Lee(University of British Columbia), Neal S. Akhave(The University of Texas MD Anderson Cancer Center), Vicente Rodrigues Marczyk(The University of Texas MD Anderson Cancer Center), Matthew S. Ning(The University of Texas MD Anderson Cancer Center), Maria Gule-Monroe(The University of Texas MD Anderson Cancer Center), Isabelle Fournier(The University of Texas MD Anderson Cancer Center), Steven G. Waguespack(The University of Texas MD Anderson Cancer Center), Renata Ferraroto(The University of Texas MD Anderson Cancer Center), Naifa L. Busaidy(The University of Texas MD Anderson Cancer Center), Anastasios Maniakas(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Jennifer Wang(The University of Texas MD Anderson Cancer Center), Luana G. Sousa(The University of Texas MD Anderson Cancer Center), Victoria E. Banuchi(The University of Texas MD Anderson Cancer Center), G. Brandon Gunn(The University of Texas MD Anderson Cancer Center), Danica M. Vodopivec(University of Alabama at Birmingham), Micheal T. Spiotto(The University of Texas MD Anderson Cancer Center), Priyanka Iyer(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|507
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
|Journal of the National Comprehensive Cancer Network|2018|370
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
|Journal of Clinical Oncology|2012|231